Latest filings (excl ownership)
RW
Registration withdrawal request
26 Apr 24
8-K
Entry into a Material Definitive Agreement
3 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
1 Apr 24
8-K
Unregistered Sales of Equity Securities
21 Mar 24
8-K
Other Events
8 Feb 24
8-K
Other Events
25 Jan 24
8-K
Departure of Directors or Certain Officers
18 Jan 24
8-K
Amendments to Articles of Incorporation or Bylaws
8 Jan 24
8-K
Titan Pharmaceuticals Announces Reverse Stock Split and Ratio
28 Dec 23
DEF 14A
Definitive proxy
28 Nov 23
PRE 14A
Preliminary proxy
17 Nov 23
8-K
Other Events
15 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
S-8
Registration of securities for employees
24 Oct 23
8-K
Titan Pharmaceuticals Announces Appointment of Dato’ Seow Gim Shen and Brynner Chiam to the Company’s Board of Directors
16 Oct 23
8-K/A
Entry into a Material Definitive Agreement
19 Sep 23
8-K
Entry into a Material Definitive Agreement
18 Sep 23
8-K
Entry into a Material Definitive Agreement
8 Sep 23
8-K
Entry into a Material Definitive Agreement
30 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets
27 Jul 23
8-K
Other Events
7 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
29 Jun 23
S-1
IPO registration
23 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Jun 23
ARS
2022 FY
Annual report to shareholders
19 May 23
DEFA14A
Additional proxy soliciting materials
19 May 23
DEF 14A
Definitive proxy
19 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
11 Apr 23
10-K
2022 FY
Annual report
31 Mar 23
8-K
Other Events
22 Mar 23
8-K
Other Events
3 Mar 23
8-K
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
9 Feb 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Jan 23
8-K
Titan Pharmaceuticals Provides Shareholder Update
15 Dec 22
8-K
Titan Pharmaceuticals Announces Licensing
12 Dec 22
10-Q
2022 Q3
Quarterly report
14 Nov 22
8-K
Departure of Directors or Certain Officers
21 Sep 22
Latest ownership filings
SC 13D/A
Sire Group Ltd.
5 Apr 24
3
Firdauz Mokhtar
5 Apr 24
3
Francisco Flores
5 Apr 24
4
Choon Hau Choong
27 Mar 24
4
DAVID NATAN
26 Oct 23
4
Matthew Charles McMurdo
26 Oct 23
4
Eric Howard Greenberg
26 Oct 23
4
Katherine Beebe
26 Oct 23
4
Avraham Ben-Tzvi
26 Oct 23
3
Brynner Chiam
23 Oct 23
SC 13D
Sire Group Ltd.
4 Oct 23
3
Seow Gim Shen
4 Oct 23
4
Eric Howard Greenberg
31 Jul 23
4/A
DAVID NATAN
31 Jul 23
4/A
Peter Louis Chasey
31 Jul 23
4/A
Matthew Charles McMurdo
31 Jul 23
4
David E. Lazar
31 Jul 23
4
Avraham Ben-Tzvi
31 Jul 23
4
Peter Louis Chasey
28 Jul 23
4
Katherine Beebe
28 Jul 23
4
Matthew Charles McMurdo
28 Jul 23
4
DAVID NATAN
28 Jul 23
SC 13D
Choong Choon Hau
20 Jul 23
3
Choon Hau Choong
20 Jul 23
4/A
David E. Lazar
28 Jun 23
4
David E. Lazar
23 Jun 23
SC 13D/A
Activist Investing LLC
23 Jun 23
4
David E. Lazar
26 Jan 23
SC 13D/A
Activist Investing LLC
15 Dec 22
3
Avraham Ben-Tzvi
30 Aug 22
3
Matthew Charles McMurdo
25 Aug 22
3
Eric Howard Greenberg
25 Aug 22
3
DAVID NATAN
25 Aug 22
3
Peter Louis Chasey
25 Aug 22
SC 13D/A
Activist Investing LLC
17 Aug 22
4
David E. Lazar
8 Jul 22
3
David E. Lazar
8 Jul 22
SC 13D/A
Activist Investing LLC
8 Jul 22
SC 13D/A
Activist Investing LLC
9 Jun 22
SC 13D
Activist Investing LLC
25 Apr 22